A61K 39/25
Varicella-zoster virus
A61K39/25 (Varicella-zoster virus) appears on 79 US grants and 129 published applications in this corpus.
Search patents in A61K- Granted patents
- 79
- Published applications
- 129
- Assignees
- 93
- Inventors
- 401
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 1 |
| 2002 | 0 | 2 |
| 2003 | 2 | 1 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 2 |
| 2007 | 1 | 2 |
| 2008 | 0 | 4 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 1 | 3 |
| 2012 | 0 | 1 |
| 2013 | 0 | 4 |
| 2014 | 1 | 4 |
| 2015 | 0 | 2 |
| 2016 | 1 | 5 |
| 2017 | 1 | 5 |
| 2018 | 4 | 7 |
| 2019 | 7 | 6 |
| 2020 | 4 | 7 |
| 2021 | 8 | 8 |
| 2022 | 4 | 12 |
| 2023 | 4 | 14 |
| 2024 | 3 | 10 |
| 2025 | 7 | 12 |
| 2026 | 8 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Vaccines, vaccine priming, and antigen dose sparing22 Sep 2026US 12,741,022 B2Adjuvance Technologies, Inc.
- Varicella zoster7 Jul 2026US 12,673,101 B2Adjuvance Technologies, Inc.
- Varicella zoster virus (VZV) vaccine12 May 2026US 12,622,960 B2ModernaTX, Inc.
- Shingles vaccines comprising a TLR9 agonist10 Mar 2026US 12,569,553 B2Dynavax Technologies Corporation
- Treatment regimen for the treatment of autoimmune disorders3 Feb 2026US 12,539,329 B2Merck Patent GmbH
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
- Mutated fragment of vzv glycoprotein e1 Oct 2026US 2026/0295035 A1
- Cpg oligonucleotide and use thereof13 Aug 2026US 2026/0232792 A1Parr Biotechnology (Hebei) Co., Ltd.
- Methods of Selecting T Cell Line and Donor Thereof for Adoptive Cellular Therapy13 Aug 2026US 2026/0232793 A1Memorial Sloan Kettering Cancer Center
- Immune Composition Product for Preventing or Treating Varicella Zoster Virus-Related Diseases and Preparation Method Therefor13 Aug 2026US 2026/0232794 A1
Most cited
By later US patents
- Varicella zoster virus (VZV) vaccine66US 11,045,540 B2ModernaTX, Inc. · 2021
- Nucleic acid vaccines for varicella zoster virus (VZV)33US 11,643,441 B1ModernaTX, Inc. · 2023
- Stabilized live vaccine29US 6,039,958 AThe Research Foundation for Microbial Diseases of Osaka University · 2000
- Process for preparing live varicella vaccines23US 3,985,615 AThe Research Foundation for Microbial Diseases of Osaka University · 1976
- Stabilized live vaccine23US 5,948,411 AThe Research Foundation for Microbial Diseases of Osaka University · 1999